Company: PRME
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038619
Chunk: 33

Company: Prime Medicine, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---
Item 1. Financial Statements (unaudited)

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in thousands, except share and per share amounts)June 30,2025December 31,2024AssetsCurrent assets:Cash and cash equivalents$53,804 $182,476 Short-term investments44,539 2,998 Short-term investment — related party3,407 4,968 Collaboration receivable — related party120 — Prepaid expenses3,032 6,777 Other current assets16,385 14,667 Total current assets121,287 211,886 Property and equipment, net23,828 24,404 Operating lease right-of-use assets120,203 47,156 Restricted cash13,691 14,062 Total assets$279,009 $297,508 Liabilities and Stockholders’ EquityCurrent liabilities:Accounts payable$6,378 $11,351 Accrued expenses and other current liabilities12,158 15,904 Deferred revenue — related party8,315 7,092 Operating lease liability7,258 3,614 Total current liabilities34,109 37,961 Deferred revenue, net of current — related party59,562 63,218 Operating lease liability, net of current112,478 37,180 Research and development funding liability12,000 6,000 Total liabilities218,149 144,359 Commitments and contingenciesStockholders’ equityCommon stock, par value of $0.00001 per share; 775,000,000 shares authorized; 134,494,438 and 131,160,842 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively2 2 Additional paid-in capital852,561 840,358 Accumulated other comprehensive loss(10)1 Accumulated deficit(791,693)(687,212)Total stockholders’ equity60,860 153,149 Total liabilities and stockholders’ equity$279,009 $297,508 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

Three Months